


ABSTRACT OF THE DISCLOSURE

A purified compound and its pharmaceutically acceptable salt that inhibits the binding between the integrin intracellular or cytoplasmic tail polypeptide and Paxillin, a pharmaceutical composition containing that compound or salt and a method of treating a biological function in an animal using that compound or salt are disclosed. The purified compound corresponds in structure to Formula I,



wherein w¹ and w², x¹, x² and x³ and Y are defined within.